Phenominer Database Results (142 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 18 0.69 x 10E6 cells/ml 0.05 0.23 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111101 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 21 2.1 x 10E6 cells/ml 0.08 0.36 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111105 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 18 987.0 cells/ul 23.81 101.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111092 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-145 days 15 median 81.7 d 3.87 15.0 necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111121 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 21 3.39 x 1000 cells/ul 0.16 0.72 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111114 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-163 days 18 89.0 % necropsy 0.0 0 two treatment fluorouracil 5-FU 111155 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-164 days 18 22.0 % necropsy 0.0 0 two treatments 5-fluorouracil + interleukin-2 111156 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-186 days 21 9.5 % necropsy 0.0 0 two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111157 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 21 81.0 % in vivo visual assessment 0.0 100 days two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111149 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 16 0.0 % in vivo visual assessment 0.0 150 days two treatment regimen saline control group 111150 3196
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2112.0 % 618.0 2140.81 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection sham surgical group POD24 111001 3191
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group A 111158 3195
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111163 3195
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111167 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group C 111172 3195
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 3.2 cm3 0.62 2.15 magnetic resonance imaging liver 0.0 31 days portal vein occlusion group POD24 portal vein occlusion group POD24 110989 3191
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-147 days 14 median 84.0 d 3.61 13.5 necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111122 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 100.0 % 0.0 0.0 necropsy 0.0 0 one treatment fluorouracil 5-FU 111125 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-157 days 15 53.0 % necropsy 0.0 0 one treatment 5-fluorouracil + interleukin-2 111128 3196
BDIX/OrlCrl liver volume after excision and regeneration DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 8.7 cm3 0.83 2.88 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection 70% hepatectomy group POD 10 110813 3191
BDIX/OrlCrl ratio of proliferating cell nuclear antigen-positive cells to total liver tumorous lesion cells DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 30 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 58.6 % 8.2 28.41 ex vivo light microscopy with immunohistochemistry liver 0.0 37 days portal vein occlusion group POD30 portal vein occlusion group POD30 110820 3191
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 17.0 null 0.89 2.0 ex vivo light microscopy with histochemistry 0.0 30 days group B 111059 3195
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 11.0 null 0.45 1.0 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111061 3195
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group C 111160 3195
BDIX/OrlCrl liver volume after excision and regeneration DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 8.1 cm3 1.07 3.71 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection portal vein occlusion group POD10 110814 3191
BDIX/OrlCrl post excision/regeneration liver volume to original liver volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 220.0 % 25.3 87.64 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection portal vein occlusion group POD10 110816 3191
BDIX/OrlCrl ratio of proliferating cell nuclear antigen-positive cells to total liver tumorous lesion cells DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 30 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 55.2 % 6.0 20.78 ex vivo light microscopy with immunohistochemistry liver 0.0 37 days 70% hepatectomy group POD30 70% hepatectomy group POD 30 110817 3191
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 10.0 null 0.45 1.0 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111063 3195
BDIX/OrlCrl calculated liver volume DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 3.73 cm3 0.21 0.73 magnetic resonance imaging liver 0.0 5 days portal vein occlusion group baseline portal vein occlusion group baseline 110812 3191
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 16 1631.0 cells/ul 149.75 599.0 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111088 3196
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.56 cm3 0.13 0.45 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection sham surgical group POD17 110992 3191
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 77 days-91 days 16 2.76 x 1000 cells/ul 0.24 0.96 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111107 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 16 1.81 x 1000 cells/ul 0.08 0.32 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111108 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 16 1.57 x 1000 cells/ul 0.06 0.24 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111109 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 18 0.3 x 1000 cells/ul 0.08 0.36 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111111 3196
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 1.67 cm3 0.38 1.32 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 70% hepatectomy group POD 24 110994 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.3 cm3 0.74 2.56 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection sham surgical group POD24 110996 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 1516.0 % 377.0 1305.97 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 70% hepatectomy group POD 24 111003 3191
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group A 111164 3195
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group B 111165 3195
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111168 3195
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-145 days 15 100.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111129 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 93.0 % necropsy 0.0 0 one treatment fluorouracil 5-FU 111133 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-162 days 15 13.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111139 3196
BDIX/OrlCrl percentage of study population developing metastatic liver tumors during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. liver integrity trait male 77 days 198 98.4 % laparotomy 0.0 14 days laparotomy (MMO:0000783) all study animals prior to treatments 111140 3196
BDIX/OrlCrl ratio of proliferating cell nuclear antigen-positive cells to total liver tumorous lesion cells DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 30 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 54.7 % 4.5 15.59 ex vivo light microscopy with immunohistochemistry liver 0.0 37 days 30% hepatectomy group POD30 30% hepatectomy group POD30 110818 3191
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111161 3195
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 0.0 % 0.0 0.0 necropsy 0.0 30 days group A 111028 3195
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 0.0 % 0.0 0.0 necropsy 0.0 30 days group 2 111032 3195
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 18 641.0 cells/ul 161.46 685.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111091 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 18 2267.0 cells/ul 74.25 315.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111093 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 18 1.23 x 10E6 cells/ml 0.05 0.23 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111103 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-140 days 14 median 77.4 d 6.95 26.0 necropsy 0.0 0 one treatment thymosin alpha-1 111118 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-157 days 15 median 94.0 d 2.63 10.2 necropsy 0.0 0 one treatment 5-fluorouracil + interleukin-2 111120 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-144 days 16 median 80.5 d 3.13 12.5 necropsy 0.0 0 saline control group 111142 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-163 days 18 median 99.7 d 4.38 18.6 necropsy 0.0 0 two treatment fluorouracil 5-FU 111143 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 21 4.5 x 1000 cells/ul 0.23 1.05 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111115 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 18 0.0 % in vivo visual assessment 0.0 150 days two treatment fluorouracil 5-FU 111151 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-144 days 16 100.0 % necropsy 0.0 0 two treatment regimen saline control group 111154 3196
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.21 cm3 0.58 2.01 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 30% hepatectomy group POD24 110995 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.9 cm3 0.16 0.55 magnetic resonance imaging liver 0.0 24 days portal vein occlusion group POD17 portal vein occlusion group POD17 110824 3191
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.8 mm 0.45 1.0 ex vivo light microscopy with histochemistry 0.0 30 days group C 111079 3195
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.9 mm 0.22 0.5 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111081 3195
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 1.78 cm3 0.38 1.32 magnetic resonance imaging liver 0.0 31 days 70% hepatectomy group POD24 70% hepatectomy group POD 24 110986 3191
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-142 days 13 median 78.5 d 3.63 13.1 necropsy 0.0 14 saline saline control group 111116 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 100.0 % 0.0 0.0 necropsy 0.0 0 one treatment interleukin-2 111127 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-147 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111130 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-141 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 111134 3196
BDIX/OrlCrl large liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 17.7 mm 0.36 0.8 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111085 3195
BDIX/OrlCrl calculated liver volume DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 3.62 cm3 0.29 1.0 magnetic resonance imaging liver 0.0 5 days 70% hepatectomy group baseline 70% hepatectomy group baseline 110811 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.7 cm3 0.12 0.42 magnetic resonance imaging liver 0.0 24 days 30% hepatectomy group POD17 30% hepatectomy group POD17 110822 3191
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 40.0 % 0.0 0.0 necropsy 0.0 30 days group B 111029 3195
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 80.0 % 0.0 0.0 necropsy 0.0 30 days group C 111030 3195
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 0.0 % 0.0 0.0 necropsy 0.0 30 days group 1 111031 3195
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-141 days 14 100.0 % 0.0 0.0 necropsy 0.0 0 one treatment thymosin alpha-1 111126 3196
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.52 cm3 0.14 0.48 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 70% hepatectomy group POD 17 110990 3191
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 77 days-91 days 16 2.25 x 10E6 cells/ml 0.18 0.72 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111097 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 16 1.17 x 10E6 cells/ml 0.07 0.3 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111098 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 18 0.43 x 10E6 cells/ml 0.02 0.11 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111100 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 16 1917.0 cells/ul 105.25 421.0 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111089 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 18 588.0 cells/ul 49.73 211.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111090 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-186 days 21 median 122.6 d 2.42 11.1 necropsy 0.0 0 two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111145 3196
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.59 cm3 0.12 0.42 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 30% hepatectomy group POD17 110991 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.79 cm3 0.15 0.52 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection portal vein occlusion group POD17 110993 3191
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 18 0.96 x 1000 cells/ul 0.06 0.25 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111110 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 18 39.0 % in vivo visual assessment 0.0 100 days two treatment fluorouracil 5-FU 111147 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 18 0.0 % in vivo visual assessment 0.0 150 days two treatments 5-fluorouracil + interleukin-2 111152 3196
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 3.09 cm3 0.62 2.15 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection portal vein occlusion group POD24 110997 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 472.0 % 127.0 439.94 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 70% hepatectomy group POD 17 110998 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2039.0 % 562.0 1946.83 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 30% hepatectomy group POD24 111004 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2839.0 % 502.0 1738.98 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection portal vein occlusion group POD24 111005 3191
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 21 9.5 % in vivo visual assessment 0.0 150 days two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111153 3196
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.8 mm 0.18 0.4 ex vivo light microscopy with histochemistry 0.0 30 days group A 111077 3195
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111162 3195
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group C 111166 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111173 3195
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-162 days 15 median 98.7 d 2.17 8.4 necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111123 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-142 days 13 100.0 % necropsy 0.0 0 saline control group 111132 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-147 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111138 3196
BDIX/OrlCrl metastatic liver tumor number DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. liver integrity trait male 77 days 198 22.0 null laparotomy 0.0 14 days laparotomy (MMO:0000783) 111141 3196
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 22.0 null 0.89 2.0 ex vivo light microscopy with histochemistry 0.0 30 days group C 111060 3195
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 12.0 null 1.34 3.0 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111062 3195
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111169 3195
BDIX/OrlCrl ratio of proliferating cell nuclear antigen-positive cells to total liver tumorous lesion cells DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 30 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 56.5 % 7.2 24.94 ex vivo light microscopy with immunohistochemistry liver 0.0 37 days sham surgical group POD30 sham surgical group POD30 110819 3191
BDIX/OrlCrl large liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 7.9 mm 0.45 1.0 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111083 3195
BDIX/OrlCrl large liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 10.1 mm 0.03 0.06 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111084 3195
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 77 days-91 days 16 2294.0 cells/ul 205.0 820.0 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111087 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 16 0.92 x 10E6 cells/ml 0.03 0.1 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111099 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 18 1.1 x 10E6 cells/ml 0.02 0.09 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111102 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 21 2.0 x 10E6 cells/ml 0.11 0.51 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111104 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-142 days 13 100.0 % 0.0 0.0 necropsy 0.0 0 saline control group 111124 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-146 days 15 median 82.7 d 3.87 15.0 necropsy 0.0 28 one treatment fluorouracil 5-FU 111117 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-146 days 15 median 83.1 d 2.32 9.0 necropsy 0.0 0 one treatment interleukin-2 111119 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-164 days 18 median 101.3 d 3.87 16.4 necropsy 0.0 0 two treatments 5-fluorouracil + interleukin-2 111144 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 18 1.88 x 1000 cells/ul 0.07 0.29 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111112 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 18 2.22 x 1000 cells/ul 0.06 0.26 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111113 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 16 19.0 % 0.0 0.0 in vivo visual assessment 0.0 100 days two treatment regimen saline control group 111146 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 18 44.0 % in vivo visual assessment 0.0 100 days two treatments 5-fluorouracil + interleukin-2 111148 3196
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 548.0 % 118.0 408.76 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 30% hepatectomy group POD17 110999 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 518.0 % 117.0 405.3 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection sham surgical group POD17 111000 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 725.0 % 151.0 523.08 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection portal vein occlusion group POD17 111002 3191
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.8 mm 0.22 0.5 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111080 3195
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.8 mm 0.18 0.4 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111082 3195
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group B 111159 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group A 111170 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group B 111171 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111175 3195
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.32 cm3 0.59 2.04 magnetic resonance imaging liver 0.0 31 days 30% hepatectomy group POD24 30% hepatectomy group POD24 110987 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.41 cm3 0.74 2.56 magnetic resonance imaging liver 0.0 31 days sham surgical group POD24 sham surgical group POD24 110988 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.63 cm3 0.14 0.48 magnetic resonance imaging liver 0.0 24 days 70% hepatectomy group POD17 70% hepatectomy group POD 17 110821 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.67 cm3 0.13 0.45 magnetic resonance imaging liver 0.0 24 days sham surgical group POD17 sham surgical group POD17 110823 3191
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-162 days 15 13.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111131 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 93.0 % necropsy 0.0 0 one treatment interleukin-2 111135 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-157 days 15 53.0 % necropsy 0.0 0 one treatment 5-fluorouracil + interleukin-2 111136 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-145 days 15 87.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111137 3196
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.2 mm 0.31 0.7 ex vivo light microscopy with histochemistry 0.0 30 days group B 111078 3195
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 12.0 null 0.89 2.0 ex vivo light microscopy with histochemistry 0.0 30 days group A 111058 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111174 3195
BDIX/OrlCrl post excision/regeneration liver volume to original liver volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 237.0 % 19.6 67.9 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection 70% hepatectomy group POD 10 110815 3191
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 40.0 % 0.0 0.0 necropsy 0.0 30 days group 3 111033 3195
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 21 3664.0 cells/ul 56.74 260.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111095 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 21 1215.0 cells/ul 87.07 399.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111094 3196